Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics
By analyzing blood serum proteomics alongside gastric tumors' omics profiles, researchers found immune features coinciding with treatment response and survival.
Caris, Xencor Ink Antibody Target Discovery Collaboration, License Agreement
Caris will apply its multiomic Discovery platform to identify new targets for drug candidates engineered via Xencor's XmAb platform.
Abcam to License Phage Library from Twist Bioscience for Antibody Discovery, Diagnostics
The deal "lays the foundations for a long-term collaboration with Abcam to drive new commercial opportunities," Twist CEO Emily Leproust said.
Twist Bioscience, Artisan Development Labs Collaborate on Antibody Discovery, Cell Therapies
Twist will receive upfront technology access and project fees; success-based clinical, regulatory, and commercial milestones; and royalties.
With $40 million in VC funding, the firm also intends to hire an international sales force and build a new generation of Cyto-Mine instruments with laser optics.